Summary

The latent TB testing market will rise in value from estimated USD 582.5 million in 2024 to USD 773.4 million in 2029, at a CAGR of 5.8% over the forecast period. Increased funding and grants for TB control programs across the globe have emerged as an important growth factor in the latent TB testing market. Substantial funding is now being committed by governments and international bodies, including WHO and the Global Fund, to address the increasing burden of TB, especially in terms of early detection and prevention. These funds are being channeled into increasing access to diagnostic facilities, especially in high-burden regions where the healthcare infrastructure is generally weak. The availability of funds also encourages the training of healthcare professionals who work with a patient to accurately diagnose and properly manage cases of latent TB. Apart from that, research grants and international collaborations are also enabling TB testing integration into routine healthcare services. Thus, this growing funding is rendering latent TB tests available and enhancing the efforts to control TB globally. This, in turn, is fuelling the growth of the global latent TB testing market.
“Interferon gamma release assay (IGRA) segment is expected to have the fastest growth rate in the latent TB testing market, by test type, during the forecast period.”
The latent TB testing market is segmented into tuberculin skin test (TST) and interferon gamma release assay (IGRA), based on test type. Interferon gamma release assay (IGRA) tests are projected to account for the highest CAGR during the forecast period. One major driving factor is its higher accuracy than conventional tuberculin skin tests (TST); IGRA tests do not suffer from interference by prior BCG vaccination, which can cause false positives for TST. Thus, IGRA is preferred in populations that have high BCG vaccination coverage. Furthermore, IGRA tends to offer faster and more consistent results, meaning that patients require fewer visits, enhancing overall efficiency in testing. Growing penetration of these tests in high-risk populations, such as patients who are immunocompromised and health care workers, continue to support increased demand. Favourable regulatory approvals and recommendations by various international health bodies, including the WHO, have also helped increase their adoption. Along with such factors, rising funding for research in TB and advancements in diagnostics are also driving the high growth of the IGRA test segment in the latent TB testing market.
“Household contacts with pulmonary TB segment accounted for the highest growth rate in the latent TB testing market, by application, during the forecast period.”
Based on application, the latent TB testing market is bifurcated into household contacts (HHC) with pulmonary tuberculosis (TB)/household contacts (HHC) of tuberculosis (TB) patients, people living with HIV, and other applications. The household contacts with pulmonary TB application segment is expected to have the highest CAGR during the forecast period. Individuals in close contact with a TB patient have a much higher probability of becoming infected with latent TB, which is the reason why regular screenings are crucial in being able to diagnose the illness early and intervene by taking preventive measures. Increasing recognition of the critical role that latent TB testing plays among high-risk groups by healthcare providers and public health agencies also drives the need for accurate latent TB diagnostics. In addition, screening of contacts across the households by the governments and TB control programs in efforts to curb latent infections from becoming active TB is further driving growth in the market segment. Collectively, all these factors are contributing to the fast growth of this application within the latent TB testing market.
“Asia Pacific: The fastest-growing region in latent TB testing market.”
The worldwide market for latent TB testing is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Notably, the Asia Pacific region is anticipated to experience the most substantial growth in the forecast period. The Asia Pacific region bears a high burden of tuberculosis, such as in India and China, which record a high incidence rate and thereby drive the need for essential latent TB screening and management. Growth in government and international organization funding and campaigns against TB has also led to better access to diagnostics and healthcare infrastructure in Asia Pacific. Awareness among the communities and among healthcare workers regarding the need for early detection of latent TB has also been significantly increasing the demand for further testing. Another major growth driver of this segment in the latent TB testing market is the increasing healthcare expenditure, along with supportive regulatory frameworks. All these factors propel increased growth of the latent TB testing market in the Asia Pacific region.
The break-up of the profile of primary participants in the latent TB testing market:
• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%
The key players in this market are QIAGEN (Netherlands), Revvity (US), Beijing Wantai Biopharmaceutical Co., Ltd. (China), Sanofi (France), Endo, Inc. (US), bioMérieux (France), SD Biosensor, INC. (South Korea), Lionex GmbH (Germany), Sanofi (France), Serum Institute of India Pvt. Ltd. (India), ARKRAY, Inc. (Japan), Zhi Fei Biological (China), AID Autoimmun Diagnostika GmbH (Germany), Boditech Med Inc. (South Korea), Bioneovan Co., Ltd (China), and Biopanda Reagents Ltd (UK).
Research Coverage:
This research report categorizes the latent TB testing market by test type (tuberculin skin test (TST) and interferon gamma release assay (IGRA)), by application (household contacts with pulmonary TB, people living with HIV, and other applications), by end user (diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the latent TB testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the latent TB testing market. Competitive analysis of upcoming startups in the latent TB testing market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall latent TB testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (rising incidence of latent tuberculosis, widespread use of BCG vaccine, and increased funding and grants for TB control programs), opportunities (Growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (changing regulatory landscape and operational barriers and labor shortage) influencing the growth of the latent TB testing market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the latent TB testing market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the latent TB testing market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the latent TB testing market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like QIAGEN (Netherlands), Revvity (US), Beijing Wantai Biopharmaceutical Co., Ltd. (China), Sanofi (France), and Endo, Inc. (US).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.3 STUDY SCOPE 26
1.3.1 MARKETS COVERED 26
1.3.2 INCLUSIONS & EXCLUSIONS 27
1.3.3 YEARS CONSIDERED 27
1.3.4 CURRENCY CONSIDERED 28
1.4 STAKEHOLDERS 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
2.1.1 SECONDARY DATA 30
2.1.1.1 Key secondary sources 30
2.1.1.2 Key data from secondary sources 31
2.1.1.3 Objectives of secondary research 31
2.1.2 PRIMARY DATA 32
2.1.2.1 Key primary sources 32
2.1.2.2 Key data from primary sources 33
2.1.2.3 Key industry insights 34
2.1.2.4 Breakdown of primaries 34
2.1.2.4.1 Breakdown of primary interviews: supply & demand-side 34
2.1.2.4.2 Breakdown of primary interviews: by company type, designation, and region 35
2.2 MARKET SIZE ESTIMATION 35
2.2.1 BOTTOM-UP APPROACH 36
2.2.1.1 Company revenue estimation approach 36
2.2.1.2 Presentations of companies and primary interviews 36
2.2.1.3 Growth forecast 37
2.2.1.4 CAGR projections 37
2.2.2 TOP-DOWN APPROACH 37
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 39
2.4 MARKET SHARE ANALYSIS 39
2.5 ASSUMPTIONS 40
2.5.1 STUDY ASSUMPTIONS 40
2.5.2 GROWTH RATE ASSUMPTIONS 40
2.6 LIMITATIONS 41
2.7 RISK ASSESSMENT 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 46
4.1 LATENT TB TESTING MARKET OVERVIEW 46
4.2 LATENT TB TESTING MARKET, BY TEST TYPE, 2024 VS. 2029 46
4.3 LATENT TB TESTING MARKET, BY APPLICATION, 2024 VS. 2029 47
4.4 LATENT TB TESTING MARKET, BY END USER, 2024 VS. 2029 47
4.5 LATENT TB TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 48
5 MARKET OVERVIEW 49
5.1 INTRODUCTION 49
5.2 MARKET DYNAMICS 49
5.2.1 DRIVERS 50
5.2.1.1 Rising incidence of latent tuberculosis 50
5.2.1.2 Widespread use of BCG vaccine 51
5.2.1.3 Increased funding and grants for TB control programs 52
5.2.2 RESTRAINTS 53
5.2.2.1 Unfavorable reimbursement scenario 53
5.2.3 OPPORTUNITIES 53
5.2.3.1 Growth opportunities in emerging economies 53
5.2.4 CHALLENGES 54
5.2.4.1 Changing regulatory landscape 54
5.2.4.2 Operational barriers and labor shortage 54
5.3 PRICING ANALYSIS 54
5.3.1 AVERAGE SELLING PRICE, BY PRODUCT 55
5.3.2 INDICATIVE PRICE OF IGRA TESTS, BY REGION 55
5.4 PATENT ANALYSIS 56
5.4.1 LIST OF MAJOR PATENTS 58
5.5 VALUE CHAIN ANALYSIS 59
5.6 SUPPLY CHAIN ANALYSIS 60
5.7 TRADE ANALYSIS 61
5.7.1 IMPORT DATA 62
5.7.2 EXPORT DATA 62
5.8 ECOSYSTEM ANALYSIS 63
5.8.1 ROLE IN ECOSYSTEM 64
5.9 PORTER’S FIVE FORCES ANALYSIS 64
5.9.1 THREAT OF NEW ENTRANTS 65
5.9.2 THREAT OF SUBSTITUTES 65
5.9.3 BARGAINING POWER OF BUYERS 66
5.9.4 BARGAINING POWER OF SUPPLIERS 66
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 66
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 66
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 67
5.10.2 KEY BUYING CRITERIA 67
5.11 REGULATORY ANALYSIS 68
5.11.1 REGULATORY LANDSCAPE 68
5.11.1.1 North America 68
5.11.1.1.1 US 68
5.11.1.1.2 Canada 68
5.11.1.2 Europe 69
5.11.1.2.1 Germany 69
5.11.1.2.2 UK 70
5.11.1.2.3 France 70
5.11.1.2.4 Italy 70
5.11.1.2.5 Spain 70
5.11.1.3 Asia Pacific 71
5.11.1.3.1 China 71
5.11.1.3.2 Japan 71
5.11.1.3.3 India 71
5.11.1.3.4 Australia 72
5.11.1.3.5 South Korea 72
5.11.1.3.6 Singapore 73
5.11.1.4 Latin America 73
5.11.1.4.1 Brazil 73
5.11.1.4.2 Mexico 74
5.11.1.5 Middle East 74
5.11.1.5.1 Africa 74
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
5.11.2.1 North America 74
5.11.2.2 Europe 75
5.11.2.3 Asia Pacific 75
5.11.2.4 Latin America 76
5.11.2.5 Rest of the world 76
5.12 TECHNOLOGY ANALYSIS 76
5.12.1 KEY TECHNOLOGIES 77
5.12.1.1 Tuberculin skin test 77
5.12.2 COMPLEMENTARY TECHNOLOGIES 77
5.12.2.1 Interferon gamma released assay 77
5.13 KEY CONFERENCES AND EVENTS, 2024–2025 78
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 79
5.15 INVESTMENT & FUNDING SCENARIO 79
5.16 CASE STUDY ANALYSIS 80
5.16.1 CASE STUDY 1: EXPLORING CYTOKINE USAGE IN MONITORING LTBI TREATMENT 80
5.16.2 CASE STUDY 2: ASSESSING DIAGNOSTIC ACCURACY OF ESAT6-CFP10 (EC) SKIN TEST FOR LTBI DETECTION 81
5.16.3 CASE STUDY 3: EVALUATING MTB-SPECIFIC CYTOKINE RESPONSES FOR ENHANCED LTBI DETECTION IN HEU INFANTS 81
5.17 LATENT TB CONTROL STRATEGIES IN MAJOR COUNTRIES 82
5.17.1 NORTH AMERICA 82
5.17.1.1 US 82
5.17.1.2 Canada 83
5.17.2 EUROPE 83
5.17.2.1 Germany 83
5.17.2.2 UK 84
5.17.3 ASIA PACIFIC 84
5.17.3.1 Japan 84
5.17.3.2 China 85
5.17.3.3 India 86
5.17.3.4 Singapore 87
5.18 IMPACT OF AI ON LATENT TB TESTING MARKET 87
5.18.1 KEY USE CASES 89
6 LATENT TB TESTING MARKET, BY TEST TYPE 90
6.1 INTRODUCTION 91
6.2 IGRA 91
6.2.1 HIGHER SPECIFICITY AND ACCURACY TO BOOST MARKET SEGMENT 91
6.3 TST 96
6.3.1 COST-EFFECTIVENESS TO PROPEL MARKET GROWTH 96
7 LATENT TB TESTING MARKET, BY APPLICATION 101
7.1 INTRODUCTION 102
7.2 PEOPLE LIVING WITH HIV 102
7.2.1 RISING RATES OF TB-HIV COINFECTION TO PROPEL GROWTH 102
7.3 HOUSEHOLD CONTACTS (HHC) WITH PULMONARY TUBERCULOSIS (TB)/ HOUSEHOLD CONTACTS (HHC) OF TUBERCULOSIS (TB) PATIENTS 106
7.3.1 NEED FOR ROUTINE SCREENING FOR HOUSEHOLD CONTACTS TO BOOST SEGMENT 106
7.4 OTHER APPLICATIONS 110
8 LATENT TB TESTING MARKET, BY END USER 115
8.1 INTRODUCTION 116
8.2 DIAGNOSTIC LABORATORIES 116
8.2.1 WELL-DEVELOPED INFRASTRUCTURE AND CAPABILITIES TO SUPPORT DEMAND FOR TESTING METHODS 116
 
8.3 HOSPITALS & CLINICS 120
8.3.1 GROWING NUMBER OF HOSPITALS AND GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT 120
8.4 ACADEMIC & RESEARCH INSTITUTES 124
8.4.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS TO SUPPORT MARKET GROWTH 124
8.5 OTHER END USERS 127
9 LATENT TB TESTING MARKET, BY REGION 131
9.1 INTRODUCTION 132
9.2 NORTH AMERICA 132
9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 133
9.2.2 US 136
9.2.2.1 US to dominate North American latent TB testing market 136
9.2.3 CANADA 140
9.2.3.1 Improved screening and treatment for latent TB to drive market 140
9.3 ASIA PACIFIC 142
9.3.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 143
9.3.2 CHINA 146
9.3.2.1 Growing public access to modern healthcare to fuel market growth 146
9.3.3 JAPAN 149
9.3.3.1 Presence of universal healthcare reimbursement policy to drive market 149
9.3.4 INDIA 151
9.3.4.1 High TB burden and growing government initiatives to drive demand for latent TB screening 151
9.3.5 SOUTH KOREA 154
9.3.5.1 Rising healthcare spending in innovative diagnostic technologies to support market growth 154
9.3.6 AUSTRALIA 157
9.3.6.1 Diverse immigrant population to fuel demand for latent TB screening 157
9.3.7 SINGAPORE 159
9.3.7.1 Enhanced healthcare infrastructure to propel market growth 159
9.3.8 REST OF ASIA PACIFIC 162
9.4 EUROPE 164
9.4.1 EUROPE: MACROECONOMIC OUTLOOK 164
9.4.2 UK 167
9.4.2.1 Growing number of diagnostic centers to fuel market 167
9.4.3 FRANCE 169
9.4.3.1 Presence of robust healthcare system to augment market growth 169
9.4.4 GERMANY 171
9.4.4.1 Higher healthcare spending and favorable government policies to favor market growth 171
 
9.4.5 SPAIN 174
9.4.5.1 Improving healthcare infrastructure to drive demand 174
9.4.6 ITALY 176
9.4.6.1 Improved quality of medical care to spur market growth 176
9.4.7 BELGIUM 178
9.4.7.1 Targeted screening for high-risk groups to fuel demand 178
9.4.8 SWEDEN 180
9.4.8.1 Growing immigrant population from high-prevalence regions to propel demand 180
9.4.9 DENMARK 182
9.4.9.1 Importance of latent TB testing in public health strategy to support market growth 182
9.4.10 REST OF EUROPE 184
9.5 LATIN AMERICA 186
9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 187
9.5.2 BRAZIL 189
9.5.2.1 Developed public health systems and improving healthcare infrastructure to favor market growth 189
9.5.3 MEXICO 191
9.5.3.1 Modernization of healthcare infrastructure to augment market growth 191
9.5.4 REST OF LATIN AMERICA 194
9.6 MIDDLE EAST & AFRICA 196
9.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 196
9.6.2 SOUTH AFRICA 198
9.6.2.1 Rising government initiatives for TB screening to augment market growth 198
9.6.3 SAUDI ARABIA 201
9.6.3.1 Enhancements in healthcare infrastructure to support market growth 201
9.6.4 UAE 203
9.6.4.1 UAE ranks among the world’s leading countries with low TB rates 203
9.6.5 KUWAIT 205
9.6.5.1 Expansion of healthcare infrastructure to augment market growth 205
9.6.6 REST OF MIDDLE EAST & AFRICA 207
10 COMPETITIVE LANDSCAPE 210
10.1 INTRODUCTION 210
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 210
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LATENT TB TESTING MARKET 210
10.3 REVENUE SHARE ANALYSIS 212
10.4 MARKET SHARE ANALYSIS 213
10.4.1 MARKET SHARE ANALYSIS, BY REGION 215
10.4.1.1 North America 215
10.4.1.2 Europe 215
10.4.1.3 Asia Pacific 216
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 216
10.5.1 STARS 216
10.5.2 EMERGING LEADERS 216
10.5.3 PERVASIVE PLAYERS 216
10.5.4 PARTICIPANTS 216
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 218
10.5.5.1 Company footprint 218
10.5.5.2 Test type footprint 218
10.5.5.3 Application footprint 218
10.5.5.4 Region footprint 219
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 219
10.6.1 PROGRESSIVE COMPANIES 219
10.6.2 RESPONSIVE COMPANIES 219
10.6.3 DYNAMIC COMPANIES 219
10.6.4 STARTING BLOCKS 219
10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 221
10.7.1 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2023 221
10.8 VALUATION & FINANCIAL METRICS 222
10.9 BRAND/PRODUCT COMPARATIVE ANALYSIS 223
10.9.1 QIAGEN 223
10.9.2 REVVITY 223
10.9.3 BIOMÉRIEUX 224
10.10 COMPETITIVE SCENARIO 224
10.10.1 PRODUCT LAUNCHES 224
10.10.2 DEALS 225
11 COMPANY PROFILES 227
11.1 KEY PLAYERS 227
11.1.1 QIAGEN 227
11.1.1.1 Business overview 227
11.1.1.2 Products offered 228
11.1.1.3 Recent developments 229
11.1.1.3.1 Product launches & approvals 229
11.1.1.3.2 Deals 229
11.1.1.3.3 Expansions 230
11.1.1.4 MnM view 230
11.1.1.4.1 Right to win 230
11.1.1.4.2 Strategic choices 230
11.1.1.4.3 Weaknesses & competitive threats 230
 
11.1.2 REVVITY (OXFORD IMMUNOTEC) 231
11.1.2.1 Business overview 231
11.1.2.2 Products offered 232
11.1.2.3 Recent developments 233
11.1.2.3.1 Product launches & approvals 233
11.1.2.4 MnM view 233
11.1.2.4.1 Right to win 233
11.1.2.4.2 Strategic choices 233
11.1.2.4.3 Weaknesses & competitive threats 234
11.1.3 BEIJING WANTAI BIOPHARMACEUTICAL CO., LTD. 235
11.1.3.1 Business overview 235
11.1.3.2 Products offered 236
11.1.3.3 MnM view 236
11.1.3.3.1 Right to win 236
11.1.3.3.2 Strategic choices 236
11.1.3.3.3 Weaknesses & competitive threats 236
11.1.4 SANOFI 237
11.1.4.1 Business overview 237
11.1.4.2 MnM view 239
11.1.4.2.1 Right to win 239
11.1.4.2.2 Strategic choices 239
11.1.4.2.3 Weaknesses & competitive threats 239
11.1.5 ENDO, INC. 240
11.1.5.1 Business overview 240
11.1.5.2 Products offered 241
11.1.5.3 MnM view 241
11.1.5.3.1 Key strengths 241
11.1.5.3.2 Strategic choices 241
11.1.5.3.3 Weaknesses and competitive threats 241
11.1.6 BIOMÉRIEUX 242
11.1.6.1 Business overview 242
11.1.6.2 Products offered 243
11.1.6.3 Recent developments 244
11.1.6.3.1 Product approvals 244
11.1.7 SD BIOSENSOR, INC. 245
11.1.7.1 Business overview 245
11.1.7.2 Products offered 246
11.1.7.3 Recent developments 246
11.1.7.3.1 Deals 246
11.1.8 LIONEX GMBH 247
11.1.8.1 Business overview 247
11.1.8.2 Products offered 247
11.1.9 SERUM INSTITUTE OF INDIA PVT. LTD. 248
11.1.9.1 Business overview 248
11.1.9.2 Products offered 248
11.1.10 ARKRAY, INC. 249
11.1.10.1 Business overview 249
11.1.10.2 Products offered 249
11.1.10.3 Recent developments 250
11.1.10.3.1 Expansions 250
11.2 OTHER PLAYERS 250
11.2.1 ZHI FEI BIOLOGICAL 250
11.2.2 AID AUTOIMMUN DIAGNOSTIKA GMBH 251
11.2.3 BODITECH MED INC. 251
11.2.4 BIONEOVAN CO., LTD. 252
11.2.5 BIOPANDA REAGENTS LTD. 252
12 APPENDIX 253
12.1 DISCUSSION GUIDE 253
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 257
12.3 CUSTOMIZATION OPTIONS 259
12.4 RELATED REPORTS 259
12.5 AUTHOR DETAILS 260